Home | Laws | Print Page | Contact Us | Report Abuse | Sign In | Register
News: Industry News

FDA move against a power opioid marks progress in addiction fight

Wednesday, June 14, 2017  
Posted by: AATA Staff
Share |
Many applauded the Food and Drug Administration’s recent announcement that the prescription opioid Opana ER (oxymorphone) should be removed from the market. Read More

Contact Us

11835 W. Olympic Blvd.
Suite 1090
Los Angeles, CA 90064


Terms, Conditions & Refunds

About AATA

The American Addiction Treatment Association (AATA) delivers reliable information and resources on compliance and best practices to enable recovery industry professionals, owners, and operators to navigate the evolving clinical and regulatory landscapes.

Connect With Us